Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas

Journal of Oncology

Volumn , Issue , 2009, Pages

  Knauer, Shirley K ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 KETOSTEROID RECEPTOR; ALPHA INTERFERON; ALPHA TOCOPHEROL; CISPLATIN; DOXORUBICIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOTRETINOIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RETINOID CID RECEPTOR BETA; RETINOID X RECEPTOR; ROSIGLITAZONE; TAMOXIFEN; THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CPG ISLAND; DOWN REGULATION; EPIGENETICS; ESOPHAGUS CANCER; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MOUTH CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA;

EID: 70350774072     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/349205     Document Type: Review

References (81)

1. Forastiere A., Weber R., Ang K., Treatment of head and neck cancer The New England Journal of Medicine 2008 358 10 1077 1078
2. Forastiere A. A., Chemotherapy in the treatment of locally advanced head and neck cancer Journal of Surgical Oncology 2008 97 8 701 707
3. Bernier J., A multidisciplinary approach to squamous cell carcinomas of the head and neck: an update Current Opinion in Oncology 2008 20 3 249 255
4. Lippert B. M., Knauer S. K., Fetz V., Mann W., Stauber R. H., Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential International Journal of Cancer 2007 121 6 1169 1174 (Pubitemid 47293781)
5. Forastiere A. A., Trotti A., Pfister D. G., Grandis J. R., Head and neck cancer: recent advances and new standards of care Journal of Clinical Oncology 2006 24 17 2603 2605
6. Forastiere A. A., Ang K. K., Brizel D., Head and neck cancers Journal of the National Comprehensive Cancer Network 2008 6 7 646 695
7. Gronemeyer H., Gustafsson J.- Å., Laudet V., Principles for modulation of the nuclear receptor superfamily Nature Reviews Drug Discovery 2004 3 11 950 964
8. Schweitzer A., Knauer S. K., Staubert R. H., Therapeutic potential of nuclear receptors Expert Opinion on Therapeutic Patents 2008 18 8 861 888
9. Vogelstein B., Kinzler K. W., Cancer genes and the pathways they control Nature Medicine 2004 10 8 789 799
10. Dahlman-Wright K., Cavailles V., Fuqua S. A., International union of pharmacology. LXIV. Estrogen receptors Pharmacological Reviews 2006 58 4 773 781
11. Osborne C. K., Schiff R., Estrogen-receptor biology: continuing progress and therapeutic implications Journal of Clinical Oncology 2005 23 8 1616 1622
12. Hamakawa H., Nakashiro K.-I., Sumida T., Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer Head and Neck 2008 30 6 800 809
13. Lukits J., Remenr., Rs E., Ladnyi A., Ksler M., Tmr J., Molecular identification, expression and prognostic role of estrogen- and progesterone receptors in head and neck cancer International Journal of Oncology 2007 30 1 155 160
14. Germain P., Staels B., Dacquet C., Spedding M., Laudet V., Overview of nomenclature of nuclear receptors Pharmacological Reviews 2006 58 4 685 704
15. Trotter K. W., Archer T. K., Nuclear receptors and chromatin remodeling machinery Molecular and Cellular Endocrinology 2007 265-266 162 167
16. Perissi V., Rosenfeld M. G., Controlling nuclear receptors: the circular logic of cofactor cycles Nature Reviews Molecular Cell Biology 2005 6 7 542 554
17. Benoit G., Malewicz M., Perlmann T., Digging deep into the pockets of orphan nuclear receptors: insights from structural studies Trends in Cell Biology 2004 14 7 369 376
18. Michalik L., Wahli W., Guiding ligands to nuclear receptors Cell 2007 129 4 649 651
19. Nettles K. W., Greene G. L., Ligand control of coregulator recruitment to nuclear receptors Annual Review of Physiology 2005 67 309 333
20. Kourelis K., Sotiropoulou-Bonikou G., Vandoros G., Varakis I., Peroxisome proliferator-activated receptor expression correlates with the differentiation level of normal, premalignant, and malignant laryngeal squamous cells Journal of Otolaryngology 2007 36 5 283 290
21. Deroo B. J., Korach K. S., Estrogen receptors and human disease Journal of Clinical Investigation 2006 116 3 561 570
22. Krishnan A., Nair S. A., Pillai M. R., Biology of PPAR gamma in cancer: acritical review on existing lacunae Current Molecular Medicine 2007 7 6 532 540
23. Yasui Y., Kim M., Tanaka T., PPAR ligands for cancer chemoprevention PPAR Research 2008 2008 10
24. Lehrke M., Lazar M. A., The many faces of PPAR Cell 2005 123 6 993 999
25. Hsueh W. A., Bruemmer D., Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease Hypertension 2004 43 2 297 305
26. Altucci L., Leibowitz M. D., Ogilvie K. M., de Lera A. R., Gronemeyer H., RAR and RXR modulation in cancer and metabolic disease Nature Reviews Drug Discovery 2007 6 10 793 810
27. Kroemer G., Pouyssegur J., Tumor cell metabolismml: cancers Achilles heel Cancer Cell 2008 13 6 472 482
28. Wang T., Xu J., Yu X., Yang R., Han Z. C., Peroxisome proliferator-activated receptor gamma in malignant diseases Critical Reviews in Oncology/Hematology 2006 58 1 1 14
29. Fajas L., Debril M. B., Auwerx J., Peroxisome proliferator-activated receptorgamma: from adipogenesis to carcinogenesis Journal of Molecular Endocrinology 2001 27 1 1 9
30. Masuda T., Wada K., Nakajima A., Critical role of peroxisome proliferator-activated receptor on anoikis and invasion of squamous cell carcinoma Clinical Cancer Research 2005 11 11 4012 4021
31. Feldman P. L., Lambert M. H., Henke B. R., PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Current Topics in Medicinal Chemistry 2008 8 9 728 749
32. Clay C. E., Namen A. M., Atsumi G.-I., Magnitude of peroxisome proliferator-activated receptor- activation is associated with important and seemingly opposite biological responses in breast cancer cells Journal of Investigative Medicine 2001 49 5 413 420
33. Jaeckel E. C., Raja S., Tan J., Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor with head and neck squamous cell carcinoma Archives of OtolaryngologyHead Neck Surgery 2001 127 10 1253 1259
34. Koeffler H. P., Peroxisome proliferator-activated receptor gamma and cancers Clinical Cancer Research 2003 9 1 1 9
35. Badawi A. F., Badr M. Z., Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma International Journal of Oncology 2002 20 6 1109 1122
36. Kopelovich L., Fay J. R., Glazer R. I., Crowell J. A., Peroxisome proliferatoractivated receptor modulators as potential chemopreventive agents Molecular Cancer Therapeutics 2002 1 5 357 363
37. Nakashiro K., Begum N. M., Uchida D., Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma Oral Oncology 2003 39 8 855 861
38. Panigrahy D., Singer S., Shen L. Q., PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis The Journal of Clinical Investigation 2002 110 7 923 932
39. Panigrahy D., Shen L. Q., Kieran M. W., Kaipainen A., Therapeutic potential of thiazolidinediones as anticancer agents Expert Opinion on Investigational Drugs 2003 12 12 1925 1937
40. Papadaki I., Mylona E., Giannopoulou I., Markaki S., Keramopoulos A., Nakopoulou L., PPARgamma expression in breast cancer: clinical value and correlation with ERbeta Histopathology 2005 46 1 37 42
41. Baetz T., Eisenhauer E., Siu L., A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours Investigational New Drugs 2007 25 3 217 225
42. Kebebew E., Peng M., Reiff E., A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer Surgery 2006 140 6 960 967
43. Whiteside T. L., The tumor microenvironment and its role in promoting tumor growth Oncogene 2008 27 45 5904 5912
44. Wang N., PPAR- in vascular pathophysiology PPAR Research 2008 2008 10
45. Kim E. H., Surh Y. J., The role of 15-deoxy-delta(12,14)-prostaglandin J(2), an endogenous ligand of peroxisome proliferator-activated receptor gamma, in tumor angiogenesis Biochemical Pharmacology 2008 76 11 1544 1553
46. Schug T. T., Berry D. C., Shaw N. S., Travis S. N., Noy N., Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors Cell 2007 129 4 723 733
47. Rochette-Egly C., Nuclear receptors: integration of multiple signalling pathways through phosphorylation Cellular Signalling 2003 15 4 355 366
48. Donato L. J., Suh J. H., Noy N., Suppression of mammary carcinoma cell growth by retinoic acid: the cell cycle control gene B t g 2 is a direct target for retinoic acid receptor signaling Cancer Research 2007 67 2 609 615
49. Donato L. J., Noy N., Suppression of mammary carcinoma growth by retinoic acid: proapoptotic genes are targets for retinoic acid receptor and cellular retinoic acid-binding protein II signaling Cancer Research 2005 65 18 8193 8199
50. Soprano D. R., Qin P., Soprano K. J., Retinoic acid receptors and cancers Annual Review of Nutrition 2004 24 201 221
51. Uma R. S., Naresh K. N., DCruz A. K., Mulherkar R., Borges A. M., Metastasis of squamous cell carcinoma of the oral tongue is associated with downregulation of epidermal fatty acid binding protein (E-FABP) Oral Oncology 2007 43 1 27 32
52. Martinez I., Wang J., Hobson K. F., Ferris R. L., Khan S. A., Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas European Journal of Cancer 2007 43 2 415 432
53. Baylin S. B., Ohm J. E., Epigenetic gene silencing in cancera mechanism for early oncogenic pathway addiction? Nature Reviews Cancer 2006 6 2 107 116
54. Virmani A. K., Rathi A., Zchbauer-Mller S., Promoter methylation and silencing of the retinoic acid receptor- gene in lung carcinomas Journal of the National Cancer Institute 2000 92 16 1303 1307
55. Sirchia S. M., Ferguson A. T., Sironi E., Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor 2 promoter in breast cancer cells Oncogene 2000 19 12 1556 1563
56. Youssef E. M., Lotan D., Issa J. P., Hypermethylation of the retinoic acid receptor- (2) gene in head and neck carcinogenesis Clinical Cancer Research 2004 10 5 1733 1742
57. Nason-Burchenal K., Gandini D., Botto M., Interferon augments PML and PML/RAR expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line Blood 1996 88 10 3926 3936
58. Shalinsky D. R., Bischoff E. D., Lamph W. W., A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice Cancer Research 1997 57 1 162 168
59. Hong W. K., Spitz M. R., Lippman S. M., Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets Journal of Clinical Oncology 2000 18 21, supplement 9s 18s
60. Lippman S. M., Lotan R., Advances in the development of retinoids as chemopreventive agents Journal of Nutrition 2000 130 supplement 2 479S 482S
61. Germain P., Chambon P., Eichele G., International union of pharmacology. LX. Retinoic acid receptors Pharmacological Reviews 2006 58 4 712 725 (Pubitemid 44833741)
62. van Zandwijk N., Dalesio O., Pastorino U., de Vries N., van Tinteren H., EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups Journal of the National Cancer Institute 2000 92 12 977 986
63. McGregor F., Muntoni A., Fleming J., Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine Cancer Research 2002 62 16 4757 4766
64. Ralhan R., Chakravarti N., Kaur J., Clinical significance of altered expression of retinoid receptors in oral precancerous and cancerous lesions: relationship with cell cycle regulators International Journal of Cancer 2006 118 5 1077 1089
65. Ralhan R., Kaur J., Retinoids as chemopreventive agents Journal of Biological Regulators and Homeostatic Agents 2003 17 1 66 91
66. Lotan R., Xu X.-C., Lippman S. M., Suppression of retinoic acid receptor- in premalignant oral lesions and its up-regulation by isotretinoin The New England Journal of Medicine 1995 332 21 1405 1410
67. Pavan B., Biondi C., Dalpiaz A., Nuclear retinoic acid receptor beta as a tool in chemoprevention trials Current Medicinal Chemistry 2006 13 29 3553 3563
68. Wrangle J. M., Khuri F. R., Chemoprevention of squamous cell carcinoma of the head and neck Current Opinion in Oncology 2007 19 3 180 187
69. Bug G., Ritter M., Wassmann B., Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia Cancer 2005 104 12 2717 2725
70. Venkov C. D., Rankin A. B., Vaughan D. E., Identification of authentic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function Circulation 1996 94 4 727 733
71. Omoto Y., Kobayashi Y., Nishida K., Expression, function, and clinical implications of the estrogen receptor in human lung cancers Biochemical and Biophysical Research Communications 2001 285 2 340 347
72. Marsigliante S., Muscella A., Resta L., Storelli C., Human larynx expresses isoforms of the oestrogen receptor Cancer Letters 1996 99 2 191 196
73. Kalayarasan R., Ananthakrishnan N., Kate V., Basu D., Estrogen and progesterone receptors in esophageal carcinoma Diseases of the Esophagus 2008 21 4 298 303
74. Nozoe T., Oyama T., Takenoyama M., Hanagiri T., Sugio K., Yasumoto K., Significance of immunohistochemical expression of estrogen receptors and in squamous cell carcinoma of the esophagus Clinical Cancer Research 2007 13 14 4046 4050
75. Vattemi E., Graiff C., Sava T., Pedersini R., Caldara A., Mandara M., Systemic therapies for recurrent and/or metastatic salivary gland cancers Expert Review of Anticancer Therapy 2008 8 3 393 402
76. Ku T. K. S., Crowe D. L., Coactivator-mediated estrogen response in human squamous cell carcinoma lines Journal of Endocrinology 2007 193 1 147 155
77. Balakumar P., Rose M., Ganti S. S., Krishan P., Singh M., PPAR dual agonists: are they opening Pandoras Box? Pharmacological Research 2007 56 2 91 98
78. Ishida H., Wada K., Masuda T., Critical role of estrogen receptor on anoikis and invasion of squamous cell carcinoma Cancer Science 2007 98 5 636 643
79. Rocha A. S., Marques R., Bento I., Thyroid hormone receptor mutations in the hot-spot region are rare events in thyroid carcinomas Journal of Endocrinology 2007 192 1 83 86
80. Hsu P. P., Sabatini D. M., Cancer cell metabolismml: warburg and beyond Cell 2008 134 5 703 707
81. Biggins J. B., Koh J. T., Chemical biology of steroid and nuclear hormone receptors Current Opinion in Chemical Biology 2007 11 1 99 110